<DOC>
	<DOCNO>NCT01335269</DOCNO>
	<brief_summary>The primary objective trial determine safety tolerability BI 853520 monotherapy define maximum tolerate dose ( MTD ) recommend dose trial development compound . Secondary objective - determination pharmacokinetic ( PK ) profile ; - exploratory pharmacodynamic analysis ; - collection preliminary data anti-tumour efficacy .</brief_summary>
	<brief_title>A Study BI 853520 Patients With Various Types Advanced Metastatic Cancer</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Inclusion criterion 1 . Patients confirm diagnosis advance , measurable evaluable , nonresectable and/or metastatic nonhematologic malignancy , show progressive last 6 month demonstrate serial image 2 . Patients fail conventional treatment therapy proven efficacy exist amenable establish treatment option 3 . Tumour tissue must available determination Ecadherin expression ( archived tissue fresh biopsy ) . 4 . Recovery reversible toxicity ( alopecia exclude ) prior anticancer therapy ( CTCAE grade &lt; 2 ) 5 . Age = 18 year 6 . Life expectancy = 3 month 7 . Written inform consent accordance International Conference Harmonisation/Good Clinical Practice ( ICH/GCP ) local legislation , include consent PK sample , use archive tumour sample determination Ecadherin status , review previous tumour scan ( provide skin biopsy , patient dose find phase enrol protocol amendment 03 ) 8 . Eastern Cooperative Oncology Group ( ECOG ) , R010787 ) performance score 01 Additional inclusion criterion expansion phase : 9 . Patients must measurable progressive disease within last 6 month , accord Response Evaluation Criteria Solid Tumours ( RECIST ) criterion ( version 1.1 , R090262 ) 10. delete 11 . Patients must willing provide pair tumour biopsy PD determination . Refer section 5.6.3 12 . Patients fit one category describe : I. Metastatic adenocarcinoma pancreas Patients preferably receive least one line systemic treatment metastatic disease preferably 2 prior regimen metastatic disease . II . Platinumresistant ovarian carcinoma , define recurrence within 6 month completion prior platinumbased chemotherapy Patients receive preferably 5 previous line systemic treatment metastatic disease . III . Oesophageal carcinoma Patients oesophageal carcinoma adenocarcinoma squamous cell histology receive preferably 2 previous line systemic treatment metastatic disease . IV . Soft tissue sarcoma Patients preferably receive 2 previous line systemic treatment metastatic disease . Exclusion criterion : Serious concomitant nononcological disease/illness Active/symptomatic brain metastasis Second malignancy Pregnancy breastfeed Women men sexually active unwilling use medically acceptable method contraception . Treatment cytotoxic anticancertherapies investigational drug within four week first treatment study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>